Clinical trials / Maryland
Psychedelic and ketamine trials recruiting in Maryland
22 trials registered on ClinicalTrials.gov were recruiting at one or more sites in Maryland on 26 Oct 2026. By substance: Psilocybin 15, Ketamine / esketamine 7, MDMA 4, DMT / ayahuasca 1. By condition: depression 6, ptsd 3, opioid use disorder 2, cancer and end-of-life distress 2.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 3Ketamine / esketamineNCT07227454
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)
- Conditions:
- Depressive Disorder, Major
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 12 Years to 17 Years, 258 participants planned
- Also in:
- Brazil, Hungary, Italy, Romania, Spain, Taiwan
- Johns Hopkins University, Baltimore, Maryland
Phase 2Psilocybin, Ketamine / esketamineNCT05403086
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC)
- Conditions:
- Demoralization
- Sponsor:
- Charles S. Grob, M.D.
- Who:
- ages 18 Years and over, 100 participants planned
- Sunstone Therapies, Rockville, Maryland
Phase 2Ketamine / esketamineNCT02543983
Neurobiology of Suicide
- Conditions:
- Healthy Volunteers; Depression
- Sponsor:
- National Institute of Mental Health (NIMH)
- Who:
- ages 18 Years to 70 Years, 325 participants planned, accepts healthy volunteers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Phase 1Ketamine / esketamineNCT03065335
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- Conditions:
- Healthy Volunteer; Major Depressive Disorder; Depression
- Sponsor:
- National Institute of Mental Health (NIMH)
- Who:
- ages 18 Years to 65 Years, 150 participants planned, accepts healthy volunteers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Early phase 1PsilocybinNCT04123314
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
- Conditions:
- Depressive Symptoms; Depression; Alzheimer Disease; Mild Cognitive Impairment
- Sponsor:
- Johns Hopkins University
- Who:
- ages 18 Years to 85 Years, 20 participants planned
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 1/2PsilocybinNCT05301608
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
- Conditions:
- Healthy
- Sponsor:
- Johns Hopkins University
- Who:
- ages 18 Years to 75 Years, 30 participants planned, accepts healthy volunteers
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 2MDMANCT05584826
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
- Conditions:
- Cancer; Adjustment Disorders
- Sponsor:
- Sunstone Medical
- Who:
- ages 18 Years and over, 20 participants planned
- Sunstone Medical, PC, Rockville, Maryland
Phase 2PsilocybinNCT06067737
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (BIPOD-Out)
- Conditions:
- Opioid Use Disorder
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years to 70 Years, 90 participants planned
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 1PsilocybinNCT06355414
Psilocybin in Chronic Low Back Pain and Depression
- Conditions:
- Chronic Low-back Pain; Depression
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years to 80 Years, 40 participants planned
- Johns Hopkins University School of Medicine, Baltimore, Maryland
Phase 2Ketamine / esketamineNCT06511908
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- Conditions:
- Suicide; Depressive Disorder, Treatment-Resistant; Ketamine; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Excitatory Amino Acid Agents; Physiological Effects of Drugs; Depressive Disorder, Major; Depressive Disorder; Depression; Mental Disorders; Mood Disorders; Behavioral Symptoms
- Sponsor:
- National Institute of Mental Health (NIMH)
- Who:
- ages 18 Years to 70 Years, 50 participants planned
- National Institutes of Health Clinical Center, Bethesda, Maryland
Early phase 1PsilocybinNCT06656702
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
- Conditions:
- Amyotrophic Lateral Sclerosis
- Sponsor:
- Johns Hopkins University
- Who:
- ages 18 Years and over, 24 participants planned
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 1PsilocybinNCT06660381
Psilocybin-assisted Treatment for Cannabis Use Disorder
- Conditions:
- Cannabis Use Disorder
- Sponsor:
- Johns Hopkins University
- Who:
- ages 18 Years and over, 12 participants planned
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 1Psilocybin, MDMA, Ketamine / esketamine, DMT / ayahuascaNCT06772753
Investigation of Psychedelic Effects in Psychoactive Substances
- Conditions:
- Psychedelic Effects in Healthy Volunteers
- Sponsor:
- Johns Hopkins University
- Who:
- ages 25 Years to 55 Years, 50 participants planned, accepts healthy volunteers
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 2PsilocybinNCT06902974
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD (SUN004)
- Conditions:
- Post Traumatic Stress Disorder; PTSD
- Sponsor:
- Sunstone Medical
- Who:
- ages 18 Years and over, 70 participants planned
- Sunstone Medical, PC, Rockville, Maryland
Phase 2Ketamine / esketamineNCT06943859
Ketamine for Opioid Use Disorder
- Conditions:
- Opioid Use Disorder
- Sponsor:
- University of Maryland, Baltimore
- Who:
- ages 18 Years to 65 Years, 50 participants planned
- University of Maryland Addiction Programs and Affiliated Clinics, Baltimore, Maryland
Phase 1Psilocybin, MDMANCT06989957
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) (PAM-VET)
- Conditions:
- Posttraumatic Stress Disorder
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years and over, 40 participants planned
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 1PsilocybinNCT07053917
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)
- Conditions:
- Stroke; Chronic Stroke; Intracerebral Haemorrhage; Intracerebral Haemorrhage (ICH); Intracerebral Hemorrhage Basal Ganglia; Ischemic Stroke; Ischemic Stroke and Hemorrhagic Stroke; Hemiparesis After Stroke; Hemiplegia Following Ischemic Stroke; Hemiplegia and Hemiparesis; Hemiplegia and/or Hemiparesis Following Stroke; Middle Cerebral Artery Stroke
- Sponsor:
- Johns Hopkins University
- Who:
- ages 18 Years and over, 20 participants planned
- Johns Hopkins, Baltimore, Maryland
Phase 1PsilocybinNCT07180108
PRoMiSS: Psilocybin and the Role of Music in Set and Setting (PRoMiSS)
- Conditions:
- Psilocybin; Music Intervention
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years to 75 Years, 100 participants planned, accepts healthy volunteers
- Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center, Baltimore, Maryland
Early phase 1PsilocybinNCT07565493
Psilocybin Administration With 5-HT1a Blockade (PsilBlock1)
- Conditions:
- Psychedelic Effects in Healthy Volunteers
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years to 60 Years, 18 participants planned, accepts healthy volunteers
- Center for Psychedelics and Consciousness Research, Baltimore, Maryland
Phase 2MDMANCT07569159
MDMA Therapy in Veterans With PTSD
- Conditions:
- Post Traumatic Stress Disorder
- Sponsor:
- Sunstone Medical
- Who:
- ages 18 Years and over, 52 participants planned
- Sunstone Therapies, Rockville, Maryland
Phase 1/2PsilocybinNCT07610135
Psilocybin Efficacy With or Without Pimavanserin Pretreatment (PRISMatic)
- Conditions:
- Mood (Psychological Function); Well Being; Mood; Healthy
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years to 65 Years, 20 participants planned, accepts healthy volunteers
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Phase 2PsilocybinNCT07721467
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
- Conditions:
- Alzheimer's Disease
- Sponsor:
- National Institute on Aging (NIA)
- Who:
- ages 65 Years to 120 Years, 200 participants planned, accepts healthy volunteers
- National Institute of Aging, Clinical Research Unit, Baltimore, Maryland